Lonza has won a contract to make an allogeneic stem-cell candidate for TiGenix at its facility in Walkersville, Maryland. Cx601 is Tigenix's expanded adipose-derived stem cell therapy for the treatment of perianal fistulas in Crohn's disease patients, and the Belgium-based company has selected Lonza to produce the product for an upcoming Phase III trial in the US.
http://ift.tt/1F6olu3?
http://ift.tt/1F6olu3?
No comments:
Post a Comment